GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz
** IND submitted to the FDA showing significantly improved patient condition when…
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz
** IND submitted to the FDA showing significantly improved patient condition when…
NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
MILAN, Dec. 5, 2024 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical…
Vevo Therapeutics Partners with the Parse Biosciences GigaLab to Generate 100M Cell Atlas for AI Powered Drug Discovery
SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a leading provider of accessible and scalable single cell…
US FDA Grants Orphan Drug Designation to EXG110, a Novel Gene Therapy for Fabry Disease
Company also Provides Updates on wet Age Related Macular Degeneration and Rare…
HUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at CurrentTerms
November 28, 2024 05:30 ET | Source: HUTCHMED (China) Limited HONG KONG…
